Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 103502

AbstractConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Reviews
Year : 2024 | Month : January | Volume : 18 | Issue : 1 | Page : OE01 - OE05 Full Version

Role of Intestinal Microbiota in the Pathogenesis of Colorectal Cancer: A Narrative Review


Published: January 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/60755.18860
Sharanya Menon, Kanishk K Adhit, Samarth Shukla, Sourya Acharya

1. Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College, DMIMS (DU), Wardha, Maharashtra, India. 2. Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College, DMIMS (DU), Wardha, Maharashtra, India. 3. Professor, Department of Pathology, Jawaharlal Nehru Medical College, DMIMS (DU), Wardha, Maharashtra, India. 4. Professor and Head, Department of Medicine, Jawaharlal Nehru Medical College, DMIMS (DU), Wardha, Maharashtra, India.

Correspondence Address :
Sharanya Menon,
Undergraduate Student, Department of Medicine, Jawaharlal Nehru Medical College, DMIMS (DU), Wardha-442004, Maharashtra, India.
E-mail: sharanyamenon5@gmail.com

Abstract

The human gut microbiota forms a biome and acts as a neglected organ, playing vital roles in organ integrity, metabolism, immunity, and homeostasis. Variations in the microbiome can lead to disease initiation. Research using bacterial sequencing of faeces and digestive tissues has focused on understanding the role of gut microbiota in cancer development, particularly Colorectal Cancer (CRC), Dysbiosis and modifications in the intestinal microbiota have been observed in CRC cases. Hypotheses like the alpha bug hypothesis and the driver-passenger model aim to explain the correlation between gut microbiota and CRC pathogenesis. The present article summarise the functions of gut microbiota, mechanisms involved in colorectal carcinogenesis, and discusses the clinical significance of gut microbiota in CRC screening and therapy.

Keywords

Diet, Dysbiosis, Gastrointestinal malignancy, Inflammation, Screening

Colorectal Cancer (CRC) is considered to be one of the common and deadliest types of cancer. It ranks third in recurrence and fourth in cancer-related mortality, causing nearly 700,000 deaths annually (1). Among males, CRC is the third most frequent cancer, while among females, it is the second most common (2). The majority of cases of CRC are reported in Western countries, with a yearly exponential increase (3). Factors such as lifestyle, chronic diseases, and age significantly influence the likelihood of developing CRC (1).

The human gut harbours a vast number of microorganisms, exceeding the total count of human cells (4). This microbial community interacts with the host to maintain homeostasis. The intestinal microbiota to play a pivotal role in the energy production, stimulates the intestinal epithelium, enhances pathogen defense, and triggers IgG antibodies (5). Gut microbiota is established early in life, acquired from the mother’s vagina and skin, and remains stable throughout one’s lifetime (6). Factors like medication, diet, exercise, and genetics influence the growth and stability of gut microbiota (7).

Destruction of the gut microbiota can havoc the normal physiological functioning, leading to various diseases (8). Recent studies on microbiota and colonic carcinoma have revealed a significant relationship, analysing the role of gut microbiota in CRC (9),(10). These studies have compared the microbial composition of patients with colorectal carcinoma to that of healthy individuals, identifying differences in microorganism abundance and depletion (9),(10).

The CRC typically originates from abnormal and uncontrolled growth of the cells lining the colon or rectum. It often begins with the formation of benign mucosal growth called a polyp. Adenocarcinoma of the colon is the most common malignancy in the Gastrointestinal (GI) tract and is recognised as the leading cause of morbidity and mortality worldwide (11).

Present study review aims to highlight the significance of intestinal microbiota in the human body, summarise relevant findings, explore the association between gut microbiota and colonic carcinoma, and discuss the potential use of gut microbial changes as biomarkers for early diagnosis and prompt treatment.

Incidence of Colorectal Cancer (CRC)

According to Global Cancer Observatory (GLOBOCAN) 2018, colonic carcinoma ranks fourth in incidence, while carcinoma of the rectum ranks eighth, making CRC the third most prevalent cancer globally (12). In 2018, approximately 1,096,000 new cases of colon cancer and 704,000 new cases of rectal cancer were reported (13). CRC is more common in males than females (11). It is about 25% more prevalent in developed countries compared to developing countries, suggesting a potential association with lifestyle patterns (13). Northern and Southern European countries, New Zealand, have higher rates of colonic cancer, while rectal cancer is more dominant in Eastern Asia, New Zealand, Australia, and Eastern European nations. North America has the highest number of reported cases for both colon and rectal cancer (14). Hungary has the highest reported cases of CRC per 100,000 population among males, and Norway leads among females. African and South Asian countries reported fewer cases of rectal and colon cancers (14). In 2018, CRC ranked as the second most common cancer globally (Table/Fig 1) (15), with 881,000 deaths. Colon cancer alone accounted for 551,000 lives, making it the fifth most fatal cancer, while rectal cancer claimed 310,000 lives, ranking it as the tenth most deadly cancer worldwide (13). The predicted five-year prevalence of CRC in India is 87 per 100,000 people. The low incidence of CRC in developing countries is believed to be influenced by variations in dietary habits and lifestyles. Additionally, there are differences influenced in the prevalence of obesity, a risk factor for CRC, between the developed and developing worlds. A study conducted by Patil PS et al., suggests another factor that contributing to the lower prevalence of CRC in the younger population, compared to the elderly, could be age-related factors (16).

Aetiology

Majority of the cases of CRC have a sporadic origin, with about 20% of patients exhibiting a positive family history on average. Genetic and environmental factors together contribute to the development of CRC. Conditions such as Lynch syndrome and serrated polyposis are closely associated with CRC (17). Familial adenomatous polyposis, caused by mutations in the adenomatous polyposis coli gene, is another prevalent syndrome linked to CRC. Patients with familial adenomatous polyposis develop multiple colorectal adenomas that progress to CRC at a young age (18). The risk of CRC is significantly increased in individuals with Inflammatory Bowel Disease (IBD), and this risk is proportional to the duration of IBD. However, only 1% of CRC cases are associated with IBD. Recent studies suggest that the prevalence of CRC in IBD patients is decreasing due to advancements in modern medicine and effective anti-inflammatory treatments (19),(20).

Various environmental factors play a crucial role in the development of CRC. Fortunately, these factors, particularly lifestyle factors, can be modified through self-discipline and following a strict regimen. Smoking and alcohol consumption increase the risk of CRC. Moderate alcohol consumption is associated with a 25% increased risk of CRC, while higher alcohol consumption raises the risk to 50% (21). Similarly, heavy smoking shows a similar trend. Increased Body Mass Index (BMI) is another factor that predisposes individuals to CRC. With each unit increase in BMI, there is an almost 3% increase in the risk of CRC (22). A sedentary lifestyle is also a major contributing factor. Daily physical activity, for at least 30 minutes, has been shown to decrease the risk of CRC (23). A well-balanced diet, rich in fibre, may help reshape the organisational structure of the gut microbiota and improve its function, thereby controlling metabolite production and promoting colonic health. The consumption of red and processed meat significantly increases the risk of colon cancer (24). The carcinogenic effects associated with red meat consumption may be attributed to the use of preservatives, additives, or chemicals in its preparation and cooking. Gut bacteria metabolise these compounds, creating molecules that contribute to the development of CRC.

Furthermore, a high-calorie diet is directly linked to an increased risk of colon cancer. Studies have shown higher levels of deoxycholic acid in CRC patients (Table/Fig 2) (25). Patients with gallstones also have higher concentrations of secondary bile acids and are at an increased risk of CRC (26).

On the other hand, consumption of vitamin D, fresh fruits and vegetables, multivitamins, calcium, milk, whole grains, and fibre is associated with a decreased incidence of CRC (25). Therefore, a shift towards consuming organic vegetables is strongly recommended. The association between dietary fibre consumption and decreased CRC risk is supported by observations of significantly lower numbers of CRC cases in African populations that consume a high-fibre diet (27). Dietary fibre can exert an anti-CRC effect, potentially due to its impact on gut microbiota. The bacteria in the gut ferment fibre to produce short-chain fatty acids, which play essential roles in regulating of metabolism and the immune system and lower the risk of CRC. Similarly, whole grains also exert their effects through the production of short-chain fatty acids. They also contain beneficial nutrients like flavonoids and polyphenols, which act as the key modulators of gut microbiota (28). These lifestyle factors contribute to the geographic and socio-economic differences in the occurrence of CRC.

Gut Microbiota

Gut microbiota refers to the collection of microorganisms, including bacteria, viruses, fungi, and other organisms, that reside in the Gastrointestinal Tract (GIT), which plays a role in maintaing the gut homeostasis. Gut microbiota has coevolved with the host and the adult human gut is inhabited approximately 100 trillion microorganisms, with considerable variation in the type and number of microorganisms along the length of the GI tract, from the mouth to the rectum (29). Bacteria make up about 70% of the microbiome. Microorganisms are classified as luminal, faecal, or mucosa-associated flora based on their location (30).

The precise number and composition of microorganisms in the human gut vary depending on the host’s lifestyle and genotype (31). Firmicutes, Bacteroidetes, and Actinobacteria are the three primary phyla whose bacteria l species are commonly found in the human gut. Bacteroides, Bifidobacterium, Atopobium, Peptostreptococcus, Eubacterium, and Fusobacterium are predominant obligate anaerobes in the intestinal microbiota. In contrast, facultative anaerobes like Enterobacteriaceae, Enterococci, Lactobacilli, and Streptococci make up a smaller portion. The composition of bacteria varies significantly along the gut (Table/Fig 3) (32), with Bacteroidetes and Actinobacteria comprising over 90% in the colon but only 50% in the small intestine. Firmicutes species constitute around 40% (29).

Functions of Gut Microbiota

Gut microbiota plays a crucial role in the development and function of the mucosal immune system, nutrient absorption, angiogenesis, and the enteric nervous system. It also affects epithelial homeostasis, wound healing, and cell renewal (33),(34),(35).

The microbiota synthesis essential vitamins such as B12, folate, thiamine, nicotinic acid, vitamin K, biotin, pyridoxine, riboflavin, and pantothenic acid. Additionally, it ferments complex carbohydrates to produce Short-Chain Fatty Acids (SCFAs) like acetate, butyrate, and propionate (36). SCFAs they regulate various cellular processes, have anti-inflammatory and anticancer effects, provide energy for colonocytes, and enhance gut barrier function. Propionate impacts human eating patterns and gluconeogenesis, while acetate and butyrate are involved in lipid formation. SCFAs also stimulate the synthesis of IL-8, which helps maintain epithelial integrity. Added to the functions mentioned above, gut microbiota prevents the colonisation of pathogens and guarantees “colonisation resistance” (37).

Function of gut microbiota in colorectal carcinogenesis: Presently, the vogue has been put into investigating the functioning of intestinal microbiota in CRC carcinogenesis. An interesting point to note is that the colon contains one-million-fold more bacteria than the small intestine, and it is estimated that there is 12-fold more cancer developing in the colon than in the intestine, indicating a possible link between intestinal microbiota and CRC (38). A critical hypothesis of CRC carcinogenesis is the concept of microbial dysbiosis (39). However, whether dysbiosis is a cause or consequence is still a conundrum among researchers. Few bacterial species, like Streptococcus Bovis, Escherichia coli, Enterococcus faecalis, and Fusobacterium spp., have been recognised, probably suspected to contribute to colorectal carcinogenesis (30).

The CRC can arise from one or a combination of four different mechanisms, namely inflammation, the effect of genotoxins, virulence factors, and oxidative stress (Table/Fig 4).

Inflammation: Studies suggest and shows an evidence of a clear link between inflammation and tumourigenesis (40). The intestinal microbiota is separated from the immune cells by a mucosal barrier, which is formed by a single sheet of enterocytes attached together by tight junctions forms the intestinal mucosal barrier (41). The intestinal mucosal barrier appears to become more permeable in CRC patients (42). This damage is caused by dextran sodium sulphate-induced colitis and ablation of a membrane-bound protease called matriptase. As a result, the altered IECs cannot create a strong mucosal barrier, allowing bacteria and their breakdown products to invade the tumour stroma. F. nucleatum and P. anaerobius play a part in developing CRC by fostering an inflammatory microenvironment (42).

Virulence factors: A prerequisite for bacteria to cause tumourigenesis is their ability to attach to the mucosal surface. F. nucleatum attaches to the mucosal surface with the help of Fusobacterium adhesin A (FadA), which, in turn, binds particularly to E-cadherin and produces an oncogenic response (43). F. nucleatum also prevents T cell activation with the help of its surface adhesin. P. anaerobius contains a surface protein known as putative cell wall binding repeat 2, which attaches to enterocytes and initiates tumour cell proliferation. S. bovis, whose number is found to be increased in CRC cases, contributes to carcinogenesis by inflammation. The AvrA protein in Salmonella causes tumourigenesis by activating STAT3 signalling and β-catenin pathways in tumour cells of the colon (44).

Genotoxins: Genotoxins produced by gut microbiota strongly affect colorectal carcinogenesis due to their DNA-damaging effects. E.coli produces colibactin, which promotes the senescence of cells and the proliferation of tumour cells (45). Typhoid toxin produced by Salmonella damages the DNA of colonic epithelial cells through the PI3K pathway (46).

Oxidative stress: The imbalance between the generation of pro-oxidative molecules and the efficiency of antioxidant defenses is known as oxidative stress. Chronic inflammation causes inflammatory cells to produce a large amount of reactive oxygen species, which can lead to Deoxyribonucleic Acid (DNA) damage, further activate oncogenes, or deactivate tumour-suppressor genes, accelerating the development of CRC (Table/Fig 5). Reactive oxygen species can potentially be directly produced by the gut microbiota. Infected macrophages with E. faecalis produce superoxide, which harms epithelial cell DNA. E. faecalis can create hydroxyl radicals, which are potent mutagens that lead to DNA mutations which, increasing the risk of chromosomal instability and CRC (47).

A significant worth mentioning is the association of the faecal bacterium prausnitzii with CRC. It is a commensal bacterium that has anti-inflammatory effects. It exerts its anti-inflammatory action by reducing the number of interferon-gamma (48).

Clinical Significance of Gut Microbiota

Application in screening: Intestinal microbiota can be utilised in the screening of CRC (49). Various studies show that the gut microbiome exhibits explicit alterations in adenomas and carcinomas (4),(9),(30). The presence of particular bacteria helps in understanding the disease state and its prognosis to some extent. For example, a higher amount of Fusobacterium nucleatum is seen in high-grade dysplasia and is associated with a shorter survival duration (50).

Therapeutic application: Gut microbiota also exhibits promising contributions in cancer therapy. Bacteroides fragilis has been shown to improve treatment results by activating T cells. Bifidobacteria, by targeting CD8+ T cells, help prevent tumour growth (51). These possible mechanisms give us hope in taking cancer treatment a step forward. However, further exploration deep into microbes and their probiotic effects has to be studied thoroughly.

Conclusion

Colorectal Cancer (CRC) is considered one of the most prevalent forms of cancer worldwide and the third most common malignant cancer. Recently, there has been significant focus on investigating the functioning of the intestinal microbiota in CRC carcinogenesis. Gut microbiota plays a pivotal role in the health and disease processes in human beings. The composition of microorganisms exhibits observable changes during the course of an illness. Extensive studies to understand the mechanism of tumour promotion and microbial co-existence in CRC help to solve the conundrum of whether dysbiosis is a cause or consequence of the disease. Further research on the exact relationship between intestinal microbiota and metabolic by-products associated with the adenoma-carcinoma sequence could lay the foundation for more therapeutic approaches to prevent and better manage CRC.

References

1.
Haggar FA, Boushey RP. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009;22(4):191-97. Doi: 10.1055/s-0029-1242458. PMID: 21037809; PMCID: PMC2796096. [crossref][PubMed]
2.
Ewing I, Hurley JJ, Josephides E, Millar A. The molecular genetics of colorectal cancer. Frontline Gastroenterol. 2014;5(1):26-30. Doi: 10.1136/flgastro-2013-100329. Epub 2013 Aug 21. PMID: 24416503; PMCID: PMC3880905. [crossref][PubMed]
3.
Wilmink AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum. 1997;40(4):483-93. Doi: 10.1007/BF02258397. PMID: 9106701. [crossref][PubMed]
4.
Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease. Front Cell Infect Microbiol. 2021;11:625913. Doi: 10.3389/fcimb.2021.625913. PMID: 33816335; PMCID: PMC8010197. [crossref][PubMed]
5.
Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol. 2012;30:149-73. Doi: 10.1146/annurev-immunol-020711-075001. Epub 2012 Jan 3. PMID: 22224779; PMCID: PMC3513328. [crossref][PubMed]
6.
Dominguez-Bello MG, Blaser MJ, Ley RE, Knight R. Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology. 2011;140(6):1713-19. Doi: 10.1053/j.gastro.2011.02.011. PMID: 21530737. [crossref][PubMed]
7.
Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. Peer J. 2019;7:e7502. Doi: 10.7717/peerj.7502. PMID: 31440436; PMCID: PMC6699480. [crossref][PubMed]
8.
Scott AJ, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019;68(9):1624-32. Doi: 10.1136/gutjnl-2019-318556. Epub 2019 May 15. PMID: 31092590; PMCID: PMC6709773. [crossref][PubMed]
9.
Png CW, Chua YK, Law JH, Zhang Y, Tan KK. Alterations in co-abundant bacteriome in colorectal cancer and its persistence after surgery: A pilot study. Sci Rep. 2022;12(1):9829. Doi: 10.1038/s41598-022-14203-z. PMID: 35701595; PMCID: PMC9198081. [crossref][PubMed]
10.
Wang H, Liu J, Li J, Zang D, Wang X, Chen Y, et al. Identification of gene modules and hub genes in colon adenocarcinoma associated with pathological stage based on WGCNA analysis. Cancer Genet. 2020;242:01-07. Doi: 10.1016/j.cancergen.2020.01.052. Epub 2020 Feb 1. PMID: 32036224. [crossref][PubMed]
11.
Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89-103. Doi: 10.5114/pg.2018.81072. Epub 2019 Jan 6. PMID: 31616522; PMCID: PMC6791134. [crossref][PubMed]
12.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. Doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593. [crossref][PubMed]
13.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. [homepage on the internet] Lyon, France: International Agency for Research on Cancer. Lyon, France: International Agency for Research on Cancer; 2020.
14.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. Doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011;61(2):134. PMID: 21296855. [crossref][PubMed]
15.
Steinke V, Engel C, Büttner R, Schackert HK, Schmiegel WH, Propping P. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome. Dtsch Arztebl Int. 2013;110(3):32-38. Doi: 10.3238/arztebl.2013.0032. Epub 2013 Jan 18. PMID: 23413378; PMCID: PMC3566622.
16.
Patil PS, Saklani A, Gambhire P, Mehta S, Engineer R, De’Souza A, et al. Colorectal Cancer in India: An audit from a tertiary center in a low prevalence area. Indian J Surg Oncol. 2017;8(4):484-90. Doi: 10.1007/s13193-017-0655-0. Epub 2017 Apr 22. PMID: 29203978; PMCID: PMC5705504. [crossref][PubMed]
17.
Pellat A, Netter J, Perkins G, Cohen R, Coulet F, Parc Y, et al. Syndrome de Lynch: quoi de neuf ? [Lynch syndrome: What is new?]. Bull Cancer. 2019;106(7-8):647-55. French. Doi: 10.1016/j.bulcan.2018.10.009. Epub 2018 Dec 4. PMID: 30527816. [crossref][PubMed]
18.
Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. Doi: 10.1186/1750-1172-4-22. PMID: 19822006; PMCID: PMC2772987. [crossref][PubMed]
19.
Stidham RW, Higgins PDR. Colorectal cancer in inflammatory bowel disease. Clin Colon Rectal Surg. 2018;31(3):168-78. Doi: 10.1055/s-0037-1602237. Epub 2018 Apr 1. PMID: 29720903; PMCID: PMC5929884. [crossref][PubMed]
20.
Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136(5):1561-67; quiz 1818-9. Doi: 10.1053/j.gastro.2009.01.064. PMID: 19422077. [crossref][PubMed]
21.
Rossi M, Jahanzaib Anwar M, Usman A, Keshavarzian A, Bishehsari F. Colorectal cancer and alcohol consumption-populations to molecules. Cancers (Basel). 2018;10(2):38. Doi: 10.3390/cancers10020038. PMID: 29385712; PMCID: PMC5836070. [crossref][PubMed]
22.
Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62(6):933-47. Doi: 10.1136/gutjnl-2013-304701. Epub 2013 Mar 12. PMID: 23481261. [crossref][PubMed]
23.
Slattery ML, Edwards S, Curtin K, Ma K, Edwards R, Holubkov R, et al. Physical activity and colorectal cancer. Am J Epidemiol. 2003;158(3):214-24. Doi: 10.1093/aje/kwg134. PMID: 12882943. [crossref][PubMed]
24.
Chan DS, Lau R, Aune D, Vieira R, Greenwood DC, Kampman E, et al. Red and processed meat and colorectal cancer incidence: Meta-analysis of prospective studies. PLoS One. 2011;6(6):e20456. Doi: 10.1371/journal.pone.0020456. Epub 2011 Jun 6. PMID: 21674008; PMCID: PMC3108955. [crossref][PubMed]
25.
Ridlon JM, Wolf PG, Gaskins HR. Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes. 2016;7(3):201-15. Doi: 10.1080/19490976.2016.1150414. Epub 2016 Mar 22. PMID: 27003186; PMCID: PMC4939921. [crossref][PubMed]
26.
Zarnescu NO, Zarnescu EC, Dumitrascu I, Chirca A, Sanda N, Iliesiu A, et al. Synchronous biliary gallstones and colorectal cancer: A single center analysis. Exp Ther Med. 2022;23(2):138. Doi: 10.3892/etm.2021.11061. Epub 2021 Dec 13. PMID: 35069819; PMCID: PMC8756434. [crossref][PubMed]
27.
Lewin MR. Is there a fibre-depleted aetiology for colorectal cancer? Experimental evidence. Rev Environ Health. 1991;9(1):17-30. Doi: 10.1515/reveh.1991.9.1.17. PMID: 1659729. [crossref][PubMed]
28.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. Doi: 10.1038/nrdp.2015.65. PMID: 27189416; PMCID: PMC4874655. [crossref][PubMed]
29.
Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823-36. Doi: https://Doi.org/10.1042/BCJ20160510. [crossref][PubMed]
30.
Gagnière J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501-18. Doi: 10.3748/wjg.v22.i2.501. PMID: 26811603; PMCID: PMC4716055. [crossref][PubMed]
31.
Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. Doi: 10.3390/microorganisms7010014. PMID: 30634578; PMCID: PMC6351938. [crossref][PubMed]
32.
Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107-18. Doi: 10.1016/j.cell.2005.05.007. PMID: 16009137. [crossref][PubMed]
33.
Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci USA. 2003;100(18):10452-59. Doi: 10.1073/pnas.1734063100. Epub 2003 Aug 15. PMID: 12923294; PMCID: PMC193582. [crossref][PubMed]
34.
O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688-93. Doi: 10.1038/sj.embor.7400731. PMID: 16819463; PMCID: PMC1500832. [crossref][PubMed]
35.
Boleij A, Tjalsma H. Gut bacteria in health and disease: A survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc. 2012;87(3):701-30. Doi: 10.1111/j.1469-185X.2012.00218.x. Epub 2012 Feb 2. PMID: 22296522. [crossref][PubMed]
36.
Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. Doi: 10.1016/B978-0-12-800100-4.00003-9. PMID: 24388214. [crossref][PubMed]
37.
Stecher B, Hardt WD. The role of microbiota in infectious disease. Trends Microbiol. 2008;16(3):107-14. Doi: 10.1016/j.tim.2007.12.008. Epub 2008 Feb 14. PMID: 18280160. [crossref][PubMed]
38.
Proctor LM. The human microbiome project in 2011 and beyond. Cell Host Microbe. 2011;10(4):287-91. Doi: 10.1016/j.chom.2011.10.001. PMID: 22018227. [crossref][PubMed]
39.
Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14. Doi: 10.1038/nature11234. PMID: 22699609; PMCID: PMC3564958. [crossref][PubMed]
40.
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-26. Doi: 10.4103/aam.aam_56_18. PMID: 31417011; PMCID: PMC6704802. [crossref][PubMed]
41.
Lee TC, Huang YC, Lu YZ, Yeh YC, Yu LC. Hypoxia-induced intestinal barrier changes in balloon-assisted enteroscopy. J Physiol. 2018;596(15):3411-24. Doi: 10.1113/JP275277. Epub 2018 Jan 1. PMID: 29178568; PMCID: PMC6068115. [crossref][PubMed]
42.
Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254-58. Doi: 10.1038/nature11465. PMID: 23034650; PMCID: PMC3601659. [crossref][PubMed]
43.
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14(2):195-206. Doi: 10.1016/j.chom.2013.07.012. PMID: 23954158; PMCID: PMC3770529. [crossref][PubMed]
44.
Lu R, Wu S, Zhang YG, Xia Y, Liu X, Zheng Y, et al. Enteric bacterial protein AvrA promotes colonic tumourigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis. 2014;3(6):e105. Doi: 10.1038/oncsis.2014.20. PMID: 24911876; PMCID: PMC4150214. [crossref][PubMed]
45.
Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 2014;63(12):1932-42. Doi: 10.1136/gutjnl-2013-305257. Epub 2014 Mar 21. PMID: 24658599. [crossref][PubMed]
46.
Martin OCB, Bergonzini A, D’Amico F, Chen P, Shay JW, Dupuy J, et al. Infection with genotoxin-producing Salmonella enterica synergises with loss of the tumour suppressor APC in promoting genomic instability via the PI3K pathway in colonic epithelial cells. Cell Microbiol. 2019;21(12):e13099. Doi: 10.1111/cmi.13099. Epub 2019 Aug 26. PMID: 31414579; PMCID: PMC6899655. [crossref][PubMed]
47.
Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumourigenesis. Proc Natl Acad Sci USA. 2011;108(37):15354-59. Doi: 10.1073/pnas.1010203108. Epub 2011 Aug 29. PMID: 21876161; PMCID: PMC3174648. [crossref][PubMed]
48.
Rossi O, van Berkel LA, Chain F, Tanweer Khan M, Taverne N, Sokol H, et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep. 2016;6:18507. Doi: 10.1038/srep18507. PMID: 26725514; PMCID: PMC4698756. [crossref][PubMed]
49.
Gao R, Gao Z, Huang L, Qin H. Gut microbiota and colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017;36(5):757-69. Doi: 10.1007/s10096-016-2881-8. Epub 2017 Jan 7. PMID: 28063002; PMCID: PMC5395603.[crossref][PubMed]
50.
Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381- 90. Doi: 10.1007/s10096-014-2081-3. Epub 2014 Mar 6. PMID: 24599709. [crossref][PubMed]
52.
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumour immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-89. Doi: 10.1126/science. aac4255. Epub 2015 Nov 5. PMID: 26541606; PMCID: PMC4873287.[crossref][PubMed]

DOI and Others

DOI: 10.7860/JCDR/2024/60755.18860

Date of Submission: Oct 15, 2022
Date of Peer Review: Nov 24, 2022
Date of Acceptance: Feb 23, 2023
Date of Publishing: Jan 01, 2024

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. NA

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Oct 17, 2022
• Manual Googling: Nov 29, 2022
• iThenticate Software: Feb 27, 2023 (16%)

ETYMOLOGY: Author Origin

EMENDATIONS: 6

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com